West's Vial2Bag DC Device Receives FDA 510(k) Clearance and CE Mark
West Pharmaceutical Services has received 510(k) clearance of the Vial2Bag DC device from the FDA, and the CE Mark for the European Union.
The Vial2Bag DC device is produced by West's subsidiary, Medimop Medical Projects and is a universal admixture device designed to enable safe, convenient, needle-free reconstitution and transfer of drug products between a vial and a standard IV bag or bottle. The device connects to the IV bag set port using a standard IV spike and can be used with all standard manufacturers' bags. Following transfer of liquid from the bag, the reconstituted drug is then transferred from the vial back into the bag.
"Intravenous infusions are one of the most universally used methods of administration in healthcare settings. Our new Vial2Bag DC device simplifies the IV admixture process and eliminates the risk of needlestick injuries and minimises potential drug exposure, making this procedure safer and more efficient for healthcare staff," said John Paproski, President, Pharmaceutical Delivery Systems, West Pharmaceutical Services. "This 510(k) clearance and CE Marking extends West's leading portfolio of needle-free reconstitution and transfer devices and will complement the currently marketed Vial2Bag and Vial Adapter devices."
The device is available for 13-mm and 20-mm diameter vials, fits all standard IV bags and is ideal for point-of-care reconstitution and admixture and can assist in compliance with the immediate use provision of USP < 797 >. Progressive Medical Inc. (PMI) will distribute the Vial2Bag DC device to hospitals in the US.
"PMI is a leading distributor of specialty medical products that focuses on high-quality products that help improve patient safety and streamline hospital procedures. They have been successful with the Vial2Bag device over the past three years, which makes the company an excellent choice to distribute the innovative Vial2Bag DC device," said Mr Paproski.
Mark Martin, President and CEO of Progressive Medical Inc., said, "At PMI, our mission is to identify innovative new products that can improve the quality of patient healthcare, so we are very excited about the launch of Vial2Bag DC, because of its potential to improve patient outcomes, and at the same time, streamline and lessen costs in the healthcare system."
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.